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1. Introduction   
The number of melanoma cases worldwide is increasing faster than any other cancer. 
Although early detection, appropriate surgery, and adjuvant therapy have improved 
outcomes, the prognosis of metastatic melanoma remains very poor. Advanced melanoma is 
still associated with an extremely poor median survival, ranging from 2 to 8 months, with 
only 5% surviving more than 5 years and remains one of the most treatment-refractory 
malignancies. Many agents have been investigated for antitumor activity in melanoma but 
the current treatment options for patients with metastatic disease are limited and non-
curative in the majority of cases (Mouawad et al, 2010).  
The treatment of a patient with metastatic melanoma depends on multiple factors including 
the overall condition and age of the patient, the sites and number of metastases, pace of the 
disease, and the patient’s wishes for treatment. Currently, the goals of treatment are directed 
toward palliation of symptoms, particularly if the improvement in the symptoms related to 
the disease exceeds the side effects associated with the therapy (Green & Schuchter, 1998). 
In advanced melanoma, single agent chemotherapy, combination chemotherapy, 
biochemotherapy (chemoimmunotherapy), targeted therapy, Toll-like receptor agonists and 
antiangiogenic therapies have been used (Bhatia et al., 2009; Chowdhury, 1999; Cohen & 
Falkson, 1998; Jilaveanu et al., 2009; Lutzky, 2010; O’Day et al, 2002; Tarhini & Agarwala, 
2006; Treisman & Garlie, 2010). 
In this chapter, classical chemotherapeutic agents, regimens and new chemotherapeutics, 
such as targeted therapies for melanoma treatment have been reviewed. 
2. Chemotherapy  
Melanoma is considered a chemotherapy-resistant disease, and systemic chemotherapy has 
failed to significantly improve the survival of patients with nonresectable metastatic 
melanoma. The disease frequently becomes refractory to the agents even after initial 
responses are observed. Despite the lack of curative effect for the patient with advanced 
metastatic disease, chemotherapy continues to play a role in palliation of the disease. 
Although many agents have been used for melanoma treatment, single agent chemotherapy 
has generally been considered ineffective. Despite the poor overall outcome with these 
agents, they are still in common use in the clinic (Treisman & Garlie, 2010).  
For stage IV melanoma, palliative systemic chemotherapy is the mainstay of treatment and 
is associated with median survival durations with combination regimens of 6-9 months and 
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5-year survival rates of approximately 6%, which are not influenced significantly by any 
therapy yet tested in rigorous multicentre cooperative group trials (Eggermont & Kirkwood, 
2004). 
2.1 Single agent chemotherapy 
A large number of clinical trials have tested different single drugs like alkylating agents, 
nitrosureas, vinca alkaloids, platinum drugs, taxanes, topoisomerase inhibitors and 
anthracyclines, but few have shown an objective response rate (<20%) or an increase in 
progression-free and overall survival rates (Mouawad et al, 2010).  
2.1.1 Alkylating agents 
Dacarbazine (DTIC) is the first US Food and Drug Administration (FDA) approved 
chemotherapeutic agent for the treatment of metastatic melanoma (Green & Schuchter, 1998; 
Mouawad et al, 2010). The response rates with dacarbazine were 15-25%, with median 
response durations of 5-6 months, but less than 5% of complete responses. Long-term 
follow-up of patients treated with DTIC alone shows that less than 2% of the patients could 
survive for 6 years (Mouawad et al, 2010, Sasse et al., 2009). DTIC is a prodrug of the 
alkylating agent 5-(3-methyltriazen-1-yl) imidazole-4-carboximide (MTIC). The drug is 
generally well tolerated, with nausea as its major side effect, which can be controlled with 
antiemetic therapy (Treisman & Garlie, 2010). Doses and schedules of DTIC vary widely, 
with no data suggest that response rates are influenced by these variables. The most 
commonly used regimen is 850-1000 mg/m2 intravenously, on day 1 only, repeated every 3 
weeks (Green & Schuchter, 1998). It can be applied 200 mg/m2 intravenously daily for 5 
days every 3 weeks (Jilaveanu et al., 2009). It is more effective for subcutaneous, lymph 
node, and pulmonary metastases (Jilaveanu et al., 2009), but it is ineffective in brain 
metastases (Marsden et al., 2010). DTIC has been used as a standard for comparing the 
efficacy of new regimens (Coit et al., 2011; Marsden et al., 2010). 
Temozolomide (TMZ), an imidazotetrazine derivative of dacarbazine, is another cytotoxic 
alkylating agent and has the same active metabolite as dacarbazine. It is usually used to 
treat solid tumors, such as brain tumors, due to its ability to cross the blood-brain barrier, 
and might therefore constitute an alternative to DTIC in treating brain metastases, for which 
dacarbazine is ineffective (Jilaveanu et al., 2009; Treisman & Garlie, 2010).  
TMZ was shown to have an objective response rate of 21% (12 of 56 patients) in a phase II 
study, with a median survival time of 5.5 months (Treisman & Garlie, 2010). Temolozomide 
was equivalent to dacarbazine in treating metastatic melanoma in a large randomized trial 
of melanoma patients with incipient metastatic disease. It was administered orally to one 
group at a dose of 200 mg/m2 for 5 days every 4 weeks and compared with dacarbazine 
administered iv at 250 mg/m2 for 5 days every 3 weeks. The median overall survival was 7.7 
months for patients treated with TMZ and 6.4 for those treated with DTIC. The 6-month 
overall survival rate was 61% and 51%, respectively; the overall survival was not statistically 
significant. The median progression-free survival was significantly longer in patients treated 
with temozolomide (1.9 months versus 1.5 months). No big differences were observed in 
toxicity between the two drugs (Jilaveanu et al., 2009). The results of another multicentre 
phase III trial that randomized 859 patients to receive DTIC vs an extended dosing schedule 
of TMZ (150 mg/m2/d on 7 consecutive days every 14 days) were recently reported. The 
investigators found no significant differences between DTIC and TMZ in objective response 
rate, progression-free survival, or  overall survival (Bhatia et al., 2009).  
www.intechopen.com
 
Chemotherapy 
 
75 
Although temozolomide administered as a single agent might have some advantages in a 
select group of patients, it has not been FDA-approved for advanced stage melanoma; 
however, it is widely used in the United States. Temozolomide and dacarbazine are being 
studied in combination with other therapies (Jilaveanu et al., 2009). The addition of IFN to 
TMZ resulted in higher response rates; however, survival was similar for both treatments 
and the combination was associated with higher toxicity. TMZ has shown promising results 
in the treatment of brain metastases from melanoma and may be a reasonable option if 
surgery or radiation is not appropriate (Quirt et al., 2007).  
In a randomized phase III study, Middleton et al. compared dacarbazine and temozolomide 
in 305 patients with advanced melanoma. They found that median survival time was 7.7 
months for patients treated with temozolomide and 6.4 months for those treated with DTIC. 
Median progression-free survival was significantly longer in the temozolomide-treated 
group (1.9 months) than in the DTIC-treated group (1.5 months) (p=0.012). No major 
difference in drug safety was observed. Temozolomide therapy improved health-related 
quality of life; more patients showed improvement or maintenance of physical functioning 
at week 12. They concluded that temozolomide demonstrated efficacy equal to that of DTIC 
and was an oral alternative for patients with advanced metastatic melanoma (Middleton et 
al., 2000). 
2.1.2 Antimicrotubular agents 
Microtubular toxins and microtubular disassembly inhibitors have both been used in 
patients with metastatic melanoma. The vinca alkaloids especially vinblastine and 
vindesine, based on their modest activities and limited toxicities, have primarily been used 
in combination therapy (Mouawad et al., 2010; Treisman & Garlie, 2010). They are not 
effective as monotherapy. Vinflunine ditartrate and vinorelbine are the other vinca alkaloid 
agents that have been used in phase II trials (Jilaveanu et al., 2009).  
Paclitaxel and docetaxel, taxanes, are microtubule disassembly inhibitors with antitumor 
activity in a variety of neoplastic diseases. Paclitaxel has been evaluated in several phase I 
and II studies, and has demonstrated an approximately 12% to 16% response rate in 
previously untreated patients. Paclitaxel is commonly used in combination with carboplatin 
in other malignancies, and was similarly tested in melanoma (Treisman & Garlie, 2010). 
Weekly administration of paclitaxel at a dose of 80 to 100 mg/m2 (on days 1, 8, and 15 every 
4 weeks) is well tolerated by most patients. Alternatively, a higher dose can be administered 
once every 3 to 4 weeks (Bhatia et al., 2009). A phase II docetaxel study showed a 12.5% 
response rate in melanoma with one of the patients having a durable complete response, 
and it still being actively studied in other combinations, with some benefit (Treisman & 
Garlie, 2010). Several studies have evaluated docetaxel, at a dose of 100 mg/m2 administered 
intravenously over 1 hour every 21 days, with response rates ranging from 15% to 19% 
(Green & Schuchter, 1998).  
Associated toxicities include fatique, alopecia, myelosuppression, neuropathy, myalgias, 
and hypersensitivity reactions (Bhatia et al., 2009).   
2.1.3 Platinum analogs 
Cisplatin and carboplatin have modest activity in patients with metastatic melanoma. Single 
agent cisplatin given at conventional doses yields a response rate of less than 10%. However, 
a phase II study that used a higher dose (150 mg/m2) of cisplatin in combination with 
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amifostine reported an objective response rate of 53%, although the responses were 
shortlived. A response rate of 19% was observed with carboplatin in a phase II study in 
chemotherapy-naive patients with metastatic melanoma. Carboplatin has also been used in 
combination with paclitaxel in previously treated patients (Bhatia et al., 2009). 
2.1.4 Nitrosoureas 
The nitrosoureas are a group of alkylating agents that act by cross-linking DNA (Treisman & 
Garlie, 2010). Carmustine (BCNU), lomustine (CCNU) and fotemustine have single-agent 
activity comparable to dacarbazine, although they cause more myelosuppression and 
alopecia. A chloroethyl nitrosourea, fotemustine rapidly crosses the blood-brain barrier and 
has been found to have encouraging activity in patients with brain metastases. When 
compared to dacarbazine in a phase III trial involving 229 patients with metastatic 
melanoma, fotemustine was associated with a higher objective response rate (15% vs 7%, 
respectively) and a trend toward improved survival (7.3 vs 5.6 months, respectively). In 
patients without brain metastases at inclusion, the median time to development of brain 
metastases was 22.7 months in the fotemustine arm vs 7.2 months in the dacarbazine arm. 
Fotemustine has not been approved by the FDA but is available in Europe (Bhatia et al., 
2009).  
In clinical practice, these agents have a limited role as single agents, but have been used in 
combination chemotherapy (Treisman & Garlie, 2010).   
2.1.5 Tamoxifen 
The identification of estrogen receptors in melanoma led to initial trials of hormonal therapy 
for the diseases, and tamoxifen, an estrogen receptor antagonist, might be considered one of 
the first targeted agents used for the therapy for melanoma. Tamoxifen was initially used as 
a single agent and then in combination with various chemotherapeutic regimens. Although 
initial studies suggested a benefit for tamoxifen as a single agent in the treatment of 
metastatic melanoma, subsequent studies showed a response rate of only 5%. In addition, 
evaluation of samples using immunostaining failed to demonstrate estrogen receptors. 
Tamoxifen could have several other effects including effects on angiogenesis, synergic 
effects with chemotherapy, and reversal of multidrug resistance. More recently, preclinical 
studies have shown that tamoxifen potentiates the cytotoxic action of chemotherapeutic 
agents, specifically DTIC and cisplatin (Green & Schuchter, 1998). Several randomized 
clinical trials have been conducted to assess the therapeutic benefit of tamoxifen in 
combination chemotherapy regimens. Cocconi et al of the Group of Italian Investigators For 
Cancer Research (GOIRC) compared DTIC alone to DTIC plus tamoxifen in a study of 117 
patients. They found a statistically significant survival advantage to tamoxifen (48 weeks 
versus 29 weeks) and a higher response rate in patients receiving DTIC and tamoxifen 
compared with DTIC alone (Cocconi & Bella et al., 1992). In another randomized clinical 
trial, Rusthoven et al of the National Cancer Institute of Canada (NCIC) conducted a 
double-blind, placebo-controlled trial comparing response rates and survival of 200 patients 
receiving the Dartmouth regimen with and without tamoxifen. There was no statistically 
significant difference between the two groups in either overall response rate or survival 
(Rusthoven & Quirt et al., 1996).  
In a metaanalysis of published randomized controlled trials involved 912 patients, it has 
been demonstrated that tamoxifen does not improve the overall response rate, complete 
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response rate, or survival rate when administered along with combined chemotherapy or 
biochemotherapy regimens (Lens et al., 2003).   
Single drugs used in metastatic melanoma have been summarized in table 1. 
 
Drugs Abbreviation
Number 
of 
patients
Dose 
Overall 
response
References 
Dacarbazine DTIC 1868 
250 mg/m2/day 
x 5 d 
15-25% Hill 2nd et al., 1979 
Temozolomide TMZ 305 
150-200 
mg/m2/day x 5 
d 
14% 
Bleehen et al., 1995; 
Newlands et al., 1992 
Carmustine BCNU 122 75-110 mg/m2 13-18% Ahmann et al., 1976 
Semustine MET-CCNU 347 130 mg/m2 16% Ahmann et al., 1976 
Fotemustine FTMU 153 
100 
mg/m2/week x 
3 w 
20-25% Jacquillat et al., 1990 
Cisplatin CDDP 114 60-150 mg/m2 15% Glover et al., 1987 
Carboplatin CBDCA 30 
400 mg/m2 iv 
every 4 weeks 
19% Evans et al., 1987 
Vindezine VDS 273 
3 mg/m2 slow iv 
(7-14 day 
intervals) 
14% Quagliana et al., 1984 
Vinblastine VLB 62 
6-8 mg/m2 slow 
iv 1/week 
13% Quagliana et al., 1984 
Docetaxel TXT 43 
100 mg/m2 iv 
every 21 days 
14% Aamdal et al., 1994 
Paclitaxel TXL 34 125-275 mg/m2 15% Einzig AI et al., 1991 
Tamoxifen TAM 172 
20 mg/day 
orally 
7% Rumke et al., 1992 
Table 1. Single drugs used in metastatic melanoma 
2.2 Combination chemotherapy 
The role of combination chemotherapy in the treatment of metastatic melanoma remains 
uncertain. Historically there have been suggestions of improved activity with combination 
regimens, but reports of high response rates have generally emerged from single institution 
studies, and when large multicentre trials have been performed they have not confirmed 
these improvements (Chowdhury et al., 1999). There are a numerous combinations of 
chemotherapy for melanoma that have been are being developed and studied. These 
regimens have generally employed DTIC or, more recently, TMZ. Larger multiinstitution 
studies and results of randomized clinical trials strongly suggest that DTIC alone is as good 
as any of the combination regimens. Various combinations of DTIC, nitrosoureas, and 
cisplatin with other chemotherapeutic agents have been extensively evaluated in phase II 
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clinical trials, with response rates ranging from 20% to 40%. The more commonly tested 
combinations are presented in table 2.  
A four-drug combination referred to as the BOLD regimen which includes bleomycin, 
vincristine, CCNU and DTIC was first studied regimen. Initial studies produced a response 
rate of 40%, with a 9% complete response rate. Follow-up phase II studies failed to confirm 
these results, with subsequent response rates falling to 4% to 20%. Another 
chemotherapeutic regimen extensively evaluated is the combination of vinblastine, cisplatin, 
and DTIC (CVD regimen), which was developed by Legha and colleagues. The response 
rates with this three-drug regimen range from 24% to 45% (Green & Schuchter, 1998). The 
Dartmouth regimen (CDBT) (McClay regimen) is a combination of cisplatin, carmustine, 
DTIC, and tamoxifen (NCCN Guidelines Version 2011 Melanoma, Treisman & Garlie, 2010). 
  
Regimen Doses Response rate 
BOLD 
Bleomycin, 15 U day 1,4 
Vincristine, 1mg/m2 day 1,4 
CCNU, 80 mg/m2 day 1 
DTIC, 200 mg/m2 day 1-5 
28-day cycles 
9%-40% 
CVD 
Cisplatin, 20 mg/m2 day 2-5
Vinblastine, 1.6 mg/m2 day 
1-5 
DTIC, 800 mg/m2 day 1 
21-day cycles 
24%-45% 
CBDT 
(Dartmouth) 
Cisplatin, 25 mg/m2 day 1-3
BCNU, 150 mg/m2 day 1 
(given every other cycle) 
DTIC, 220 mg/m2 day 1-3 
Tamoxifen, 20 mg/day 
21-day cycles 
19%-55% 
Table 2. Combination chemotherapy regimens in metastatic melanoma 
In a large phase III study comparing the CVD regimen to DTIC alone, there was a trend 
toward improved response and survival. The Dartmouth regimen originally resulted in a 
55% response rate in the initial series of 20 patients with metastatic melanoma (Treisman & 
Garlie, 2010). A phase III multicentre trial that randomized 240 patients to the Dartmouth 
regimen vs dacarbazine monotherapy did not show a statistically significant benefit in favor 
of the combination. Despite a modest difference in objective response rate in favor of CDBT 
over DTIC (16.8% and 9.9%, respectively; p=.13), there was no significant difference in 
overall survival (7.7 and 6.3 months, respectively; p=.52). Myelosuppression, fatique, 
nausea, and vomiting were significantly higher in the CDBT arm (Chapman et al., 1999).  
Sileni et al. compared the activity and toxicity of the combination of dacarbazine, 
carmustine, cisplatin and tamoxifen (DBDT regimen) versus DTIC alone in patients with 
metastatic melanoma. Sixty patients were randomly assigned to receive BCNU 150 mg/m2 
intravenously on day 1, cisplatin 25 mg/m2 iv. daily on days 1 to 3, DTIC 220 mg/m2 iv 
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daily on days 1 to 3 and tamoxifen 160 mg orally daily for 7 days prior to chemotherapy 
(DBDT arm). Treatment cycles were repeated every 28 days, while BCNU was given every 
two cycles. The DTIC arm patients received DTIC alone 1200 mg/m2 iv on day 1, repeated 
every 21 days. The overall response rate was 26% in the DBDT arm and 5% in the DTIC arm. 
Complete responses were 2.5% for DBDT and 0% for DTIC. The median progression-free 
survival and median survival were 4 and 9 months, respectively for DBDT, and 2 and 7 
months for DTIC. DBDT was associated with significant haematological toxicity: 33% of the 
patients experienced a grade III or IV neutropenia and 28% a grade III or IV 
thrombocytopenia. The overall response rate obtained with DBDT was greater than that 
obtained with DTIC alone; however, this combination increased toxicity (Sileni et al., 2001).   
The combination of paclitaxel and carboplatin (PC) has been reported to have antitumor 
activity in patients with metastatic melanoma, including patients who have received prior 
chemotherapy (Bhatia et al., 2009).   
Zimpfer-Rechner et al. performed a randomized, multicentre, second-line clinical phase II 
study of paclitaxel either as monotherapy or combined with carboplatin given on an 
outpatient basis. In arm A, paclitaxel was administered at a dose of 100 mg/m2 
intravenously on day 1 each week for 6 weeks. In arm B, paclitaxel was administered at a 
dose of 80 mg/m2 intravenously followed by carboplatin 200 mg/m2 on day 1 each week for 
6 weeks. The next cycle was administered after a 2 week intermission. The study was 
stopped after 40 patients because the overall response rate was below 10% in both arms. The 
median survival time after initiation of second-line treatment was 209 days for patients 
treated with paclitaxel only, and 218 days for those treated with paclitaxel/carboplatin. The 
median time to progression was around 56 days in both arms. Paclitaxel with or without 
carboplatin had only limited efficacy, and the combination of these drugs adds significantly 
to haematological toxicity without improving response or survival rates (Zimpfer-Rechner 
et al., 2003). 
Rao et al. published their results with the combination of paclitaxel and carboplatin in 31 
patients with metastatic melanoma. These patients had a median of two previous therapies, 
with the majority (29; 94%) having failed prior temozolomide or dacarbazine therapy. The 
most commonly used regimen was weekly paclitaxel (at a dose of 100 mg/m2) and 
carboplatin administered on days 1,8, and 15 of a 28-day cycle. An objective partial response 
was noted in 8 patients (26%) with an additional 6 patients (19%) having stable disease; a 
clinical benefit was noted in 45% of those patients treated. The median time to disease 
progression was 3 months (range, 0-7 mos), with a median overall survival of 7.8 months 
(range, 1-14 mos). They concluded that the combination of paclitaxel and carboplatin 
appeared to have definite and clinically meaningful activity when used as second-line 
therapy after temozolomide or dacarbazine (Rao et al., 2006). 
In a report on synthesis of randomized trials, 48 studies having 111 active treatment arms 
(24 with dacarbazine monotherapy, n=1390; 75 with dacarbazine combinations, n=4962; 12 
with non-dacarbazine treatments, n=783) treating 7135 patients were examined. Response to 
dacarbazine monotherapy ranged between 5.3% and 28% (average 15.3%). Partial responses 
comprised 73% of successes. Only adding interferons improved response rates but survival 
duration was not significantly longer. All other treatments alone or in combination were 
ineffective (Lui et al., 2007). 
A listing of major randomized studies evaluating DTIC versus drug combination is 
summarized in table 3. 
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Control arm 
dacarbazine 
dose/schedule 
Study arm drugs 
(dose/schedule) 
No. of 
randomised 
patients 
Overall 
response 
(%) 
Overall 
survival 
(months) 
Study by 
2 mg/kg/day 
(iv) × 10 days 
Carmustine 150 mg/m2 
(iv) + vincristine 2 mg/m2 
(iv) on day 1 only 
50 22 vs 25 NA 
Bellet et al., 
1976 
250 mg/m2 
(iv) on days 1–
5 every 3 
weeks 
Cisplatin 20 mg/m2/day 
for 4 days starting on day 
2 + vinblastine 1.6
mg/m2/day × 5 days +
dacarbazine 800 mg/m2 
(iv) on day 1 
104 11 vs 24 5 vs 6 
Buzaid et 
al., 1993 
1000 mg/m2 
bid short iv 
infusion every 
3 weeks 
Tamoxifen 10 mg twice 
daily by mouth 1 week 
before chemotherapy 
+carmustine 150 mg/m2 on 
day 1+dacarbazine 220 
mg/m2 (iv)+cicplatin 25 
mg/m2/days 1-3 
240 
10.2 vs 
18.5 
6.3 vs 7.7 
Chapman 
et al., 1999 
250 mg/m2 (iv) 
for 4 days 
every 3 weeks 
Dacarbazine 250 mg/m2 
(iv) days 1–4 every 3 
weeks + detorubicin 120
mg/m2 iv every 3 weeks 
51 15 vs 36 5 vs 6 
Chauvergne 
et al., 1982 
1200 mg/m2 
day 1 every 3 
weeks 
Carmustine 150 mg/m2 
(iv) on day 1 + cisplatin 25
mg/m2 (iv)/day on days 
1–3 + dacarbazine 220
mg/m2 (iv)/day on days 
1–3 + tamoxifen 160 mg 
orally/day × 7 days prior 
to chemotherapy. 
Treatment cycles repeated 
every 28 days, BCNU every 
2 cycles 
60 6 vs 26 7 vs 9 
Chiarion 
Sileni et al., 
2001 
2.5 mg/m2 
(I.V.) injection 
on days 1–4 
every 4 weeks 
Dacarbazine 2.5 mg/m2 
(iv) by means of bolus 
injection on days 1–4 every 
4 weeks +
corynebacterium parvum 
7 mg (im) 1 week before 
starting DTIC and at 4-
week intervals thereafter 
49 22 vs 27 5 vs 5 
Clunie et 
al., 1980 
250 mg/m2 on 
days 1–5 every 
3 weeks 
Dacarbazine 250 mg/m2 
(iv) × 5 days, every 3-
weeks + tamoxifen 20
mg/m2 orally daily 
117 12 vs 28
11.8 vs 
7.25 
Cocconi et 
al., 1992 
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Control arm 
dacarbazine 
dose/schedule 
Study arm drugs 
(dose/schedule) 
No. of 
randomised 
patients 
Overall 
response 
(%) 
Overall 
survival 
(months) 
Study by 
200 mg/m2 
(iv) for 5 days 
repeated every 
3 weeks 
po methyl-CCNU 200
mg/m2 once every 6 weeks
Dacarbazine 150 mg/m2 
(iv) × 5 days/3 weeks + po 
methyl-CCNU 130
mg/m21/6 weeks 
415 
15 vs 15
15 vs 14
4.0 vs 4.2 
4.0 vs 4.0 
Costanza et 
al., 1977 
250 mg/m2 
(iv) on days 1–
5 every 3 
weeks 
Dacarbazine 250 mg/m2 
(iv)/day on days 1–5 +
epirubicin 90 mg/m2 on 
day 1 every 3 weeks 
42 9 vs 21 NA 
Lopez et 
al., 1984 
250 mg/m2 
(iv) on days 1–
10 every 4 
weeks 
Vinblastine 6 mg/m2/day 
(iv) on days 1–2 + 24-h 
infusion of bleomycin 15
units/m2 from days 1–5 +
cisplatin 50 mg/m2 1 h (iv) 
infusion on day 5. After 
four courses, vinblastine 
and cisplatin were given 
alone. Courses repeated on 
a cycle of 4 weeks
77 14 vs 10
4.1 vs 
3.42 
Luikart et 
al., 1984 
300
mg/m2/day ×
6 days every 
month days. 
Dacarbazine 100
mg/m2/8 h × 6 days every 
month days 
Carmustine 150 mg/m2 +
vincristine 2 mg/m2 every 
30 days 
120 
32 vs 29
32 vs 24
8.5 vs 8.4 
8.5 vs 6.5 
Moon et 
al., 1975 
250
mg/m2/day 
(iv) for 5 days 
every 4 weeks 
Dacarbazine 250
mg/m2/day (iv) × 5 days 
every 4 weeks + vindesine 
3 mg/m2/week 
119 18 vs 25 4.1 vs 5.7 
Ringborg 
et al., 1989 
220 mg/m2 on 
days 1–3, q 21 
days 
Dacarbazine 220 mg/m2 on 
day 1–3 + carboplatine 
AUC 5, day 1, q 21 days 
148 
11.7 vs 
21.3 
7 vs 9 
Babovic et 
al., 2008 
200
mg/m2/day 
(iv) for 5 days 
every 28 days 
Arm 2: (I.V.) IFN-α 15
MU/m2/day days 1–5 × 3 
weeks, then (sc) 10 MU/m2
3×/week + dacarbazine 
200 mg/m2 daily (iv) days 
1–5 starting on day 22, 
every 28 days 
Arm 3: orally tamoxifen 20
mg/day starting day 1 +
dacarbazine 200
mg/m2/day 
280 
15 vs 21
15 vs 18
15 vs 19
9.99 vs 
9.33 
9.99 vs 
7.97 
9.99 vs 
9.54 
Falkson et 
al., 1998 
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Control arm 
dacarbazine 
dose/schedule 
Study arm drugs 
(dose/schedule) 
No. of 
randomised 
patients 
Overall 
response 
(%) 
Overall 
survival 
(months) 
Study by 
(iv) days 1–5 every 28 days
Arm 4: (iv) IFN-α 15
MU/m2/day days 1–5 × 3 
weeks, then (sc) 10 MU/m2
3×/week + orally 
tamoxifen 20 mg/day 
starting day 1 +
dacarbazine 200
mg/m2/day (iv) days 1–
5/28 days
800 mg/m2 
(iv) on days 1 
and 21 
Dacarbazine 800 mg/m2 
(iv) days 1 and 21 + daily 
(im) INF-α 3 MIU at days 
1–3, 6 MlU days 4–6, and 9
MIU daily thereafter. 
Started concomitantly 
Dacarbazine 800 mg/m2 
(iv) days 1 and 21 + (IM) 
INF-α 3 MIU 3×/week. 
Started concomitantly 
266 
20 vs 28
20 vs 23
11 vs 13 
11 vs 11 
Bajetta et 
al., 1994 
800 mg/m2 
(iv) every 3 
weeks 
Dacarbazine (iv) escalating 
dose 200 mg/m2, 400
mg/m2, 800 mg/m2/3 
weeks; sc IFN-α starting at 
3 MU/day on days 1–3, 9
MU/day on days 4–70, 
then 9 MU 3×/week 
170 17 vs 21
7.36 vs 
6.27 
Thomson 
et al., 1993 
Table 3. Key randomized studies evaluating dacarbazine (DTIC) vs drug combination 
2.3 Biochemotherapy  
Biochemotherapy, the combination of chemotherapy and biologic response modifiers, was 
developed in the early 1990s to improve response rates and durable remissions in metastatic 
melanoma. The initial regimens were given sequentially (chemotherapy followed by 
biologic response modifiers) because of concern of toxicity if all the drugs were given 
simultaneously. Paradoxically, sequential regimens were highly toxic because of the 
duration of treatment (10 to 14 days) and the combined and non-overlapping toxicities of 
chemotherapy and biologic response modifiers (O’day et al., 2002). An outpatient 
biochemotherapy regimen (carmustine, cisplatin, dacarbazine, tamoxifen, IL-2 and 
interferon with lower dose subcutaneous IL-2 and interferon) was developed by Thompson 
et al (Thompson et al., 1997). The first concurrent inpatient biochemotherapy regimen was 
developed by Legha et al. „Legha regimen“ combined cisplatin, vinblastine and dacarbazine 
(CVD) chemotherapy with continuous infusion IL-2 (9 MU/m2 per day) for 4 days and 5 
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days of subcutaneous interferon alfa (5 MU/m2 per day) at 21-day intervals. The results 
were encouraging with an overall response rate of 64%, a complete response rate of 21%, 
median survival of 12 months, and a 2-year survival rate of 10%. Efficacy was comparable to 
the inpatient sequential regimens, but the regimen was significantly less toxic. 
Fever/neutropenia occured in 64% of patients and was the most significant reversible 
toxicity (Legha et al., 1998; O’day et al., 2002). The Legha regimen was subsequently 
modified by McDermott et al. to reduce toxicity. The modifications included reduction in 
the vinblastine dose, empiric granulocyte colony-stimulating factor (G-CSF) posttreatment, 
routine 5-HT3 antagonist anti-emetic therapy, prophylactic antibiotics, frequent changes in 
central lines, dose reductions for toxicity, and limitation of treatment to a maximum of 4 
cycles of therapy (McDermott et al., 2000). In a phase II trial with these modifications, 
toxicity was improved and the response rate was 48%, the complete remission rate was 20%, 
and the median survival was 11 months. Fever/neutropenia was not observed. G-CSF has 
now become a standard component of concurrent biochemotherapy regimens. Further 
modifications of the Legha regimen have been published with decrescendo dosing of 
continuous infusion IL-2. The rationale for decrescendo dosing of IL-2 is based on improved 
clinical response and reduced cumulative IL-2 toxicity (O’day et al., 2002). 
Ridolfi et al conducted a multicenter prospective randomized clinical trial in outpatients 
with metastatic melanoma to compare chemotherapy with biochemotherapy using 
immunomodulant doses of IL-2 and IFNα-2b. They randomized 176 patients with advanced 
melanoma to receive chemotherapy (cisplatin and dacarbazine with or without carmustine 
every 21 days) or biochemotherapy comprising the same chemotherapy regimen followed 
by low-dose subcutaneous IL-2 for 8 days and IFNα-2b three times a week, both for six 
cycles. At a median follow-up of 18 (chemotherapy) and 16 (biochemotherapy) months, 
median overall survival was 9.5 versus 11.0 months (p=.51), respectively. Treatment-related 
toxicity was fairly similar in both groups. They concluded that the addition of low-dose 
immunotherapy did not produce a significant advantage in overall survival, time to 
progression, or overall response (Ridolfi et al., 2002).  
Bajetta et al. investigated the effects of additional cytokines to chemotherapy in 151 
untreated metastatic melanoma patients. 75 patients received cisplatin 30 mg/m2 on days 1-
3, vindesine 2.5 mg/m2 on day 1 and dacarbazine 250 mg/m2 on days 1-3. 76 patients 
received same CVD scheme plus interferon-α2b on days 1-5 and interleukin-2 on days 1-5 
and 8-15, both administered subcutaneously, either recycled every 3 weeks. 10% of the 
patients were alive at a median of 52 months from start of therapy. They observed a 
response rate of 21% on arm A versus 33% on arm B; three patients (4%) given 
biochemotherapy had complete responses. Median time to progression was identical; 
median overall survival time was 12 months on arm A and 11 months on arm B. They also 
concluded that biochemotherapy was not better than chemotherapy alone, therefore 
biochemotherapy can not be recommended as standard first-line therapy for metastatic 
melanoma (Bajetta et al., 2006). 
3. Novel targeted agents  
The mitogen-activated protein kinase pathway plays a key role in melanoma development 
and is an important therapeutic target. Disregulation of this pathway may result in 
increased signalling activity leading to proliferation, invasion, metastasis, migration, 
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survival and angiogenesis. Activating mutations in the BRAF and NRAS genes have been 
found to be relatively frequent in melanoma, occurring in approximately 50-60% and 15% of 
tumors, respectively (Lutzky, 2010). It has been shown that mutations in the KIT gene are 
more frequent in patients with melanomas arising from mucosal, acral and sun-damaged 
skin primary sites. NRAS and BRAF mutated melanomas are more commonly derived from 
non sun-damaged skin (Curtin et al., 2005; Curtin et al., 2006). 
Recent reports describing major responses in KIT-mutated melanomas treated with imatinib 
mesylate and other drugs that inhibit KIT tyrosine kinase have led to larger trials of imatinib 
mesylate in mutation enriched populations, in an attempt to confirm that mutated KIT is a 
clinically important target in this small subpopulation of patients with melanoma. The most 
common BRAF mutation in melanoma (in 90% of BRAF-mutated melanomas) is the V600E 
mutation, which activates BRAF 500-fold. Sorafenib inhibits the BRAF serine/threonine 
kinase as well as various receptor tyrosine kinases, with significant activity in the VEGFR. 
Two randomized clinical trials testing sorafenib in combination with chemotherapy in 
melanoma produced negative results. The most likely explanation is that sorafenib is not 
very active against V600E mutated BRAF kinase. More specific BRAF-targeting drugs have 
been developed are under investigation. In a phase I trial recently published, PLX4032, an 
oral, selective inhibitor of oncogenic V600E BRAF kinase, induced complete or partial tumor 
regression in 81% of patients who had melanoma with the V600E BRAF mutation, with 
responses being observed in all sites of disease. Cutaneous side effects, fatigue and 
arthralgia were the most common side effects (Lutzky, 2010).  
In a phase II study evaluating the effects of sorafenib in advanced melanoma, a total of 101 
patients received placebo plus dacarbazine (n=50) or sorafenib plus dacarbazine (n=51). On 
day 1 of a 21-day cycle, patients received intravenous dacarbazine 1000 mg/m2 for a 
maximum of 16 cycles. Oral sorafenib 400 mg or placebo was administered twice a day 
continuously. Median progression-free survival in the sorafenib plus dacarbazine arm was 
21.1 weeks versus 11.7 weeks in the placebo plus dacarbazine arm (p=0.068). There were 
statistically significant improvements in progression-free survival rates at 6 and 9 months, 
and in time to progression in favour of the sorafenib plus dacarbazine arm. No difference in 
overall survival was observed. Sorafenib plus dacarbazine was well tolerated in patients 
with advanced melanoma and yielded an encouraging improvement in progression-free 
survival (McDermott et al., 2008). Hauschild et al reported a phase III randomized, placebo-
controlled study on the efficacy and safety of sorafenib with carboplatin and paclitaxel in 
advanced melanoma who had progressed on a dacarbazine-or temozolomide-containing 
regimen. A total of 270 patients were randomly assigned to receive intravenous paclitaxel 
225 mg/m2 plus intravenous carboplatin at area under curve 6 (AUC 6) on day 1 of a 21-day 
cycle followed by either placebo (n=135) or oral sorafenib 400 mg (n=135) twice daily on 
days 2 to 19. The median progression-free time was 17.9 weeks for the placebo plus 
carboplatin arm and 17.4 weeks for the sorafenib plus carboplatin arm (p=.49). Response 
rate was 11% with placebo versus 12% with sorafenib. Grade III thrombocytopenia, 
diarrhea, and fatigue were more common in patients treated with sorafenib plus carboplatin 
versus placebo plus carboplatin. The addition of sorafenib to carboplatin did not  
improve any of the end points over placebo plus carboplatin in this study (Hauschild et al., 
2009).   
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BAY 43-9006 is a novel RAF inhibitor that inhibits B-RAF and C-RAF. It is orally available 
and has been shown to be well tolerated. In a phase I/II trial of BAY 43-9006 in combination 
with carboplatin and paclitaxel, 35 melanoma patients were treated for at least 6 weeks. 
Among 32 evaluable patients, 11 (34%) had partial responses, including 10 ongoing at 3-16 
months. Nineteen patients had stable disease as best response. The combination 
demonstrated activity in melanoma and had a favourable safety profile and no apparent 
pharmacokinetic interactions (Tarhini & Agarwala, 2006). 
Angiogenesis and signalling through the ref/mitogen-activated protein/extracellular signal-
regulated kinase/extracellular signal-regulated kinase cascade have been reported to play 
important roles in melanoma. Ref/mitogen-activated protein/extracellular signal-regulated 
kinase inhibitor AZD6244 is a new targeted agent for advanced melanoma (Friday & Adjei, 
2008). Other important molecular pathways have been found to be altered in melanoma, 
opening new avenues for therapeutic intervention. These include the phosphatidylinositol-
3-kinase, microphtalmia-associated transcription factor, cyclin-dependent kinases, notch-1 
and iNOS pathways. Early clinical trials with drugs that are active in these pathways are 
being conducted (Lutzky, 2010).  
4. Conclusion  
Metastatic melanoma has remained refractory to systemic treatment for decades. Single-
agent or combination chemotherapy or biologic response modifiers alone have not resulted 
in response rates of durable remissions that are high enough to affect median survival. In 
the past decade, biochemotherapy regimens have been developed that appear to produce 
systemic response in approximately 50% patients and durable remissions in 10% to 20%. 
Modified concurrent biochemotherapy regimens have preserved efficacy and reduced 
toxicity, thus allowing for larger community-based clinical trials that are currently ongoing. 
These trials will determine the role of biochemotherapy as first-line treatment for metastatic 
disease. Further understanding of the molecular and immunologic mechanisms that 
promote survival of melanoma tumor cells will undoubtedly lead to the development of 
better, more specific and perhaps less toxic agents.  
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cutaneous melanoma of intermediate thickness has a beneficial effect on recurrence rates, and adjuvant
radiotherapy to regional lymph node fields following surgical resection reduces loco-regional recurrence in
patients at high risk of relapse. Isolated limb perfusion, electrochemotherapy, and photodynamic therapy
continue to be evaluated for treatment of stage IV disease. However, the greatest excitement in new treatment
has been with targeted therapies for genetic mutations. In particular, the promising results of partial and
complete tumor response in stage IV disease from early phase trials of the B-RAF kinase inhibitors. This book
provides a contemporary insight into the therapeutic treatment options for patients with metastatic melanoma
and is relevant to clinicians and researchers worldwide. In addition, an update on current clinical trials for
melanoma treatment has been included, and two chapters have been reserved to discuss the treatment of oral
and uveal melanoma.
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